GEN Exclusives

More »

GEN News Highlights

More »
Aug 24, 2009

French Government Awards TcL Roughly $3.15M for Research on CD28 Antagonists in Transplant Therapy

  • French biopharma company TcL Pharma received a €2.2 million (about $3.15 million) grant from the French National Research Agency to help fund its Tolestim project, which focuses on long-acting CD28 antagonists for the improved tolerance in transplantation.

    The research project will involve a collaboration between TcL and and Inserm laboratory, which has developed a new approach to immunosuppression based on selective CD28 antagonists. TcL’s role will include preclinical validation of the immunomodulatory effects of CD28, preparation for Phase I and IIa trials in healthy volunteers and kidney transplant patients, plus development of an industrial-scale biomanufacturing process.

    The ANR grant comes just weeks after TcL completed a €1 million (roughly $1.43 million) equity financing round as part of France’s TEPA economic stimulus package. 

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?